Science Explorer Back to mapMap
Discussion
Company · Buffalo · United States

Canget BioTekpharma (United States)

canget-biotek.comROR OpenAlex
Research works
6
▲ 3% vs 2018-21
Citations
355
55.9 per fractional work
Top-10% rate
23.0%
all institutions 10.0%
Open access
96%
world 40%
International
21%
world 18%
Canget BioTekpharma (United States)

Not ranked overall: Canget BioTekpharma (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Canget BioTekpharma (United States) work in?

In all years, 67% of research at Canget BioTekpharma (United States) is in Life Sciences, 28% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (65%), Medicine (28%), Immunology and Microbiology (3%). It does 1.8× the world's share of Life Sciences.

Life Sciences: 4 fractional works · 67.5% of its workBiochemistry, Genetics and Molecular Biology: 4 fractional works · 64.8% of its workMolecular Biology: 3 fractional works · 54.1% of its workCancer Research: 0 fractional works · 6.3% of its workCell Biology: 0 fractional works · 2.7% of its workBiotechnology: 0 fractional works · 1.7% of its workImmunology and Microbiology: 0 fractional works · 2.7% of its workImmunology: 0 fractional works · 2.7% of its workHealth Sciences: 2 fractional works · 27.8% of its workMedicine: 2 fractional works · 27.8% of its workOncology: 1 fractional works · 16.2% of its workEpidemiology: 0 fractional works · 6.9% of its workNeurology: 0 fractional works · 2.7% of its workPulmonary and Respiratory Medicine: 0 fractional works · 2.0% of its workPhysical Sciences: 0 fractional works · 4.7% of its workChemistry: 0 fractional works · 2.4% of its workOrganic Chemistry: 0 fractional works · 2.4% of its workEngineering: 0 fractional works · 1.6% of its workBiomedical Engineering: 0 fractional works · 1.6% of its workMaterials Science: 0 fractional works · 0.8% of its workBiomaterials: 0 fractional works · 0.8% of its workALL ITS WORKCangetBioTekpharma…6fractional works, all years
Life Sciences67%Physical Sciences5%Health Sciences28%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 6 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology464.8%
    2. Immunology and Microbiology02.7%
    1. Medicine227.8%
    1. Chemistry02.4%
    2. Engineering01.6%
    3. Materials Science00.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

What are the most cited papers from Canget BioTekpharma (United States)?

The most cited paper from Canget BioTekpharma (United States) is "Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?" (Fengzhi Li, Ieman A. M. Aljahdali, Xiang Ling, 2019), with 271 citations. Next come "Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?" (226) and "Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma" (114).

Most cited papers
#PaperReleasedCitations
1 Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? Fengzhi Li, Ieman A. M. Aljahdali, Xiang Ling · Journal of Experimental & Clinical Cancer Research Open access 22 Aug 2019 271
2 Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Fengzhi Li, Tao Jiang, Qingyong Li et al. · PubMed Open access 2017 226
3 Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma Fengzhi Li, Ieman A. M. Aljahdali, Renyuan Zhang et al. · Journal of Experimental & Clinical Cancer Research Open access 12 Aug 2021 114
4 FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance David Westover, Xiang Ling, Hong Lam et al. · Molecular Cancer Open access 23 Apr 2015 74
5 An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer Xiang Ling, Wenjie Wu, Chuandong Fan et al. · Journal of Experimental & Clinical Cancer Research Open access Oct 2018 68
All 20 most cited papers, with filters and sorting

Which research topics does Canget BioTekpharma (United States) publish most on?

By volume in 2022-now: Ubiquitin and proteasome pathways, RNA modifications and cancer, RNA Research and Splicing and Protein Degradation and Inhibitors.

Ubiquitin and proteasome…0Ubiquitin and proteasome pathways: 0 fractional worksRNA modifications and ca…0RNA modifications and cancer: 0 fractional worksRNA Research and Splicing0RNA Research and Splicing: 0 fractional worksProtein Degradation and …0Protein Degradation and Inhibitors: 0 fractional worksCell death mechanisms and regulation: 0 fractional worksCancer therapeutics and mechanisms: 0 fractional worksMicrotubule and mitosis …0Microtubule and mitosis dynamics: 0 fractional worksDNA Repair Mechanisms0DNA Repair Mechanisms: 0 fractional worksHistone Deacetylase Inhi…0Histone Deacetylase Inhibitors Research: 0 fractional worksATP Synthase and ATPases…0ATP Synthase and ATPases Research: 0 fractional works
Molecular BiologyCell Biology

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Ubiquitin and proteasome pathways Molecular Biology 0 works
  2. 2 RNA modifications and cancer Molecular Biology 0 works
  3. 3 RNA Research and Splicing Molecular Biology 0 works
  4. 4 Protein Degradation and Inhibitors Molecular Biology 0 works
  5. 5 Cell death mechanisms and regulation Molecular Biology 0 works
  6. 6 Cancer therapeutics and mechanisms Molecular Biology 0 works
  7. 7 Microtubule and mitosis dynamics Cell Biology 0 works
  8. 8 DNA Repair Mechanisms Molecular Biology 0 works
  9. 9 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
  10. 10 ATP Synthase and ATPases Research Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available95.8%not open4.2%

World: 40% of research is openly available.

with international co-authors21.0%domestic only79.0%

World: 18% is written across borders.

How has Canget BioTekpharma (United States)'s research output changed?

Output in 2022-2025 was 3% higher than in 2018-2021.

still counting20202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Canget BioTekpharma (United States) as a percentage of every work published that year, 0.0000045% in 2024.

still counting0.000010%0.000020%0.000030%Canget BioTekpharma (United States)0.0000058% in 20252020

Fractional works of Canget BioTekpharma (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Buffalo

All research institutions in Buffalo

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Canget BioTekpharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.